Biogen (BIIB) PT Lowered to $200 at Barclays
Tweet
Share
E-mailGet Alerts BIIB Hot Sheet
Price: $210.01 +0.09%
Rating Summary:
28 Buy, 15 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 12 | Down: 23 | New: 20
Rating Summary:
28 Buy, 15 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 12 | Down: 23 | New: 20
Join SI Premium – FREE
Barclays analyst Carter Gould lowered the price target on Biogen (NASDAQ: BIIB) to $200.00 (from $215.00) while maintaining a Equalweight rating.
You May Also Be Interested In
- Wolfe Research Upgrades Biogen (BIIB) to Outperform
- Rakus Co Ltd (3923:JP) PT Raised to JPY1,300 at Macquarie
- Candel Therapeutics Inc. (CADL) PT Raised to $15 at Freedom Broker
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
